Abstract
The methanol extract from Salvia miltiorrhiza Bungee showed a suppressive effect on umu gene expression of the SOS response in Salmonella typhimurium TA1535 / pSK1002 against the mutagen, Trp-P-1, which requires liver metabolizing enzyme. The methanol extract was successively re-extracted with dichloromethane, butanol, and water. Three suppressive compounds were isolated by SiO2 column chromatography from dichloromethane fraction and identified as tanshinone IIA (1), tanshinone I (2) and Cryptotanshinone (3) by GC, GC-MS, 1H- and 13C-NMR spectroscopy. Compounds 1, 2 and 3 inhibited the SOS-inducing activity of Trp-P-1 in the umu test. Gene expression was suppressed by 76%, 96% and 81% at less than 0.18 μmol / mL, 9 respectively. The ID50 (50% inhibition dose) values were 0.03 μmol / mL 0.008 μmol / mL and 0.010 μmol / mol, respectively. These compounds were assayed with activated Trp-P-1. Compound 2 showed suppressive effect of SOS-inducing activity of activated Trp-P-1 but compounds 1 and 3 did not.
Keywords: salvia miltiorrhiza bunge, diterpenoid, tanshinone, sos response, umu test, antimutagen
Letters in Drug Design & Discovery
Title: Suppressive Components in Salvia miltiorrhiza Against Trp-P-1 and Activated Trp-P-1-Induced SOS Response Using Salmonella typhimurium TA1535 / pSK1002 Umu Test
Volume: 1 Issue: 1
Author(s): Yoshiharu Okuno and Mitsuo Miyazawa
Affiliation:
Keywords: salvia miltiorrhiza bunge, diterpenoid, tanshinone, sos response, umu test, antimutagen
Abstract: The methanol extract from Salvia miltiorrhiza Bungee showed a suppressive effect on umu gene expression of the SOS response in Salmonella typhimurium TA1535 / pSK1002 against the mutagen, Trp-P-1, which requires liver metabolizing enzyme. The methanol extract was successively re-extracted with dichloromethane, butanol, and water. Three suppressive compounds were isolated by SiO2 column chromatography from dichloromethane fraction and identified as tanshinone IIA (1), tanshinone I (2) and Cryptotanshinone (3) by GC, GC-MS, 1H- and 13C-NMR spectroscopy. Compounds 1, 2 and 3 inhibited the SOS-inducing activity of Trp-P-1 in the umu test. Gene expression was suppressed by 76%, 96% and 81% at less than 0.18 μmol / mL, 9 respectively. The ID50 (50% inhibition dose) values were 0.03 μmol / mL 0.008 μmol / mL and 0.010 μmol / mol, respectively. These compounds were assayed with activated Trp-P-1. Compound 2 showed suppressive effect of SOS-inducing activity of activated Trp-P-1 but compounds 1 and 3 did not.
Export Options
About this article
Cite this article as:
Okuno Yoshiharu and Miyazawa Mitsuo, Suppressive Components in Salvia miltiorrhiza Against Trp-P-1 and Activated Trp-P-1-Induced SOS Response Using Salmonella typhimurium TA1535 / pSK1002 Umu Test, Letters in Drug Design & Discovery 2004; 1 (1) . https://dx.doi.org/10.2174/1570180043485635
DOI https://dx.doi.org/10.2174/1570180043485635 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Gene Therapies for Cardiovascular and Renal Diseases by Nucleic Acid Medicines
Medicinal Chemistry New Drugs and Treatment Regimens
Current Respiratory Medicine Reviews Galactolipids as Potential Health Promoting Compounds in Vegetable Foods
Recent Patents on Food, Nutrition & Agriculture A Short Review of Diffusion Models and their Possibilities to Enhance Imaging Biomarkers for Neurodegenerative Diseases
Current Medical Imaging Lipids, Statins and Heart Failure: An Update
Current Pharmaceutical Design The Role of Reactive Species in Epileptogenesis and Influence of Antiepileptic Drug Therapy on Oxidative Stress
Current Neuropharmacology Treatment of Disability in Peripheral Arterial Disease: New Drugs
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot Topic: The Evolution of Cell Therapy Towards Enhancing Vascular Regeneration in the Clinic (Guest Editors: Drew Kuraitis and Erik J. Suuronen)]
Current Vascular Pharmacology Historical Hallmarks of Anticoagulation and Antiplatelet Agents
Current Pharmaceutical Design Systemic Oxidative Stress in Older Patients with Mild Cognitive Impairment or Late Onset Alzheimer's Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Cardiology Reviews Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke
Current Pharmaceutical Design Traditional Risk Factors for Coronary Atherosclerosis in Indo Asians: The Need for a Reappraisal
Current Pharmaceutical Design Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Synthesis and the Evaluations in vitro Antiplatelet Aggregation Activities of 4-Ethoxyisophthalamides
Cardiovascular & Hematological Agents in Medicinal Chemistry HGF as Angiogenic Factor and Therapeutic Approach
Current Signal Transduction Therapy Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?
Current Medicinal Chemistry The Complications of Bariatric Surgery Patients with Type 2 Diabetes in the World: A Systematic Review and Meta-Analysis
Current Diabetes Reviews Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review
Current Medicinal Chemistry